|
Having spent the last 4 years running an implementation science research project on reversing type 2 diabetes (T2D) in primary care, I have a fair appreciation of how overwhelmed the system has become, and how fraught the day-to-day reality is for those working in it. The picture differs across countries, but a common thread runs through most: general practitioners are given less and less time per consultation, and chronic disease is consuming an ever-larger share of that time. Something in this equation has to give. The usual response is to call for more doctors. But is workforce shortage really the whole story, or is the model of care itself no longer fit for purpose? My general practitioner (GP) colleague, Dr Glen Davies, has some strong thoughts on this, and his rural New Zealand practice has spent several years quietly testing an answer. Glen’s starting point is that general practice ‘was largely designed for the diseases of the twentieth century … acute infectious diseases, trauma and episodic illness’, where a patient became unwell, was diagnosed, treated and recovered. Chronic metabolic disease does not follow that script. Obesity, hypertension, type 2 diabetes, dyslipidaemia and fatty liver disease now dominate the caseload, yet, as Glen puts it, they are still ‘often treated as separate diseases, each with its own guideline, recall system and medication pathway’, when in fact they are frequently different expressions of the same underlying insulin resistance.
That single reframing, from a collection of separate diagnoses to one shared underlying process, changes what a practice actually does from the ground up. Glen summarises the contrast starkly (see Table 1):
I asked Glen what changed when his practice stopped treating these as separate diseases. His answer was disarmingly simple: the clinical question shifted from ‘which medication should be added next?’ to ‘what is driving this patient’s metabolic dysfunction, and how can we help reverse it?’ Nutrition, physical activity, sleep, stress management and social connection became first-line treatment where appropriate, with medication retained but no longer treated as the default endpoint. The organisational change followed the conceptual one. Glen’s team now includes GPs trained in metabolic health and health coaching, nurses trained in behavioural change, a nutritionist and a Health Improvement Practitioner. The GP’s role narrows to diagnosis, ruling out serious pathology and managing complexity, while ongoing coaching and follow-up sit with the wider team. As Glen frames it, ‘this allows each member of the team to work closer to the top of their scope’, and, counterintuitively, it has let one full-time GP care for around 2000 enrolled patients, above the 1300–1500 the Royal New Zealand College of General Practitioners regards as sustainable,1 without the model collapsing under its own weight. The outcomes so far are what make this worth a journal’s attention rather than a staffroom conversation. Within Glen’s practice, 33.6% of patients with type 2 diabetes have achieved drug-free remission (metformin aside) at some point during follow-up, alongside improvements in weight, blood pressure, liver function and glycaemic control more broadly (Davies G 2026, personal communication, July 01). Diabetes costs New Zealand an estimated NZ$2.1 billion annually, projected to reach NZ$3.5bn by 2040.2 Extrapolating national cost averages to the roughly 42 patients who achieved remission in his practice suggests savings in the order of NZ$387 000.00 a year (Davies G 2026, personal communication, July 01), an estimate Glen rightly calls illustrative rather than proven, pending formal health economic evaluation. The temptation with a story this encouraging is to overreach, and Glen resists it. This is one rural practice, not a randomised trial: whether the model holds in urban, more diverse, or longer-followed populations remains unknown. What it does establish is that an alternative to lifelong disease management is feasible, and that the usual metrics of primary care activity may be measuring the wrong thing if the goal is health rather than throughput. Glen’s proof of concept does not settle the argument about whether general practice needs redesign rather than incremental reform, and it will need testing through multicentre implementation studies and pragmatic trials rather than enthusiasm alone. But it is a serious enough attempt, and produces a large enough signal, that the argument deserves to be had in the open, with the evidence base it warrants, rather than dismissed as one clinician’s optimism. If we are serious about the sustainability of primary care, the question cannot remain how to manage more disease more efficiently. It has to become how we create health. Ultimately, it is about patients feeling like active participants in their health rather than passive recipients of medications. That is not simply a system redesign question. It is, at its core, a question of metabolic health, and it is exactly the argument this journal exists to advance. Glen’s practice suggests the answer is not naive. It suggests it might be overdue.
References
|